Britain and America have concluded a key commercial pact that will maintain zero import taxes on UK medicine shipments being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on drugs through the NHS. This pledge guarantees that tariffs on these crucial products will stay at zero for a duration of 36 months.
This development is in response to recent warnings to dramatically increase import taxes on patented pharmaceutical imports, with potential rates floated reaching 100%.
"This deal between the UK reinforces the worldwide climate for new treatments and brings long-overdue balance to transatlantic pharmaceutical trade," a release declared.
Trade Impact
Pharmaceuticals represent one of the UK's largest export categories to the US, which is by far the largest destination for leading UK drugmakers.
Export figures indicate that in the year leading up to September, the UK shipped drugs totaling £11.1bn to the US. This value accounted for a significant portion of British export trade in that timeframe.
"This deal protects work, boosts investment and sets the stage for the UK to become a global hub for biotech and pharma," a minister remarked.
Specific UK Commitments
The pact includes several notable changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on treatments from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be capped at fifteen percent. In the past, refunds topped 20%.
Broader Context
This agreement takes place against a ongoing row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
These tensions were heightened by assertions that American customers were charged significantly more for the equivalent treatments than people in the other developed nations.
Recently, several large manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
